European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2022, Volume and Issue: 36(9), P. 1409 - 1431

Published: Aug. 18, 2022

Abstract The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline Consensus Statement Development Manual. Four consensus conferences were held between December 2020 July 2021. Twenty‐nine experts (including clinicians patient representatives) from 12 European countries participated. This first part of includes general information its scope purpose, health questions covered, target users a methods section. It also provides guidance which patients should be treated systemic therapies, as well recommendations detailed each drug. treatment options discussed comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab tralokinumab) janus kinase inhibitors (abrocitinib, baricitinib upadacitinib). Part two will address avoidance provocation factors, dietary interventions, immunotherapy, complementary medicine, educational occupational psychodermatological aspects, perspective considerations for paediatric, adolescent, pregnant breastfeeding patients.

Language: Английский

---

JAK inhibitors in the treatment of atopic dermatitis

Journal of Allergy and Clinical Immunology, Journal Year: 2021, Volume and Issue: 148(4), P. 927 - 940

Published: Aug. 24, 2021

Language: Английский

---

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Dec. 8, 2022

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with heterogeneous manifestations that can substantially affect patients' quality life. AD has complex pathogenesis, making treatment challenging for dermatologists. The Janus kinase (JAK)–signal transducer and activator transcription (STAT) pathway plays central role in modulating multiple immune axes involved the immunopathogenesis AD. In particular, Th2 cytokines, including interleukin (IL)-4, IL-5, IL-13, IL-31, thymic stromal lymphopoietin, which contribute to symptoms chronic inflammation pruritus AD, are mediated by JAK–STAT signal transduction. Furthermore, regulation epidermal barrier modulation peripheral nerves related transduction pruritus. Targeting may attenuate these signals show clinical efficacy through suppression various pathways associated Topical oral JAK inhibitors variable selectivity have emerged as promising therapeutic options Notably, topical ruxolitinib, upadacitinib, abrocitinib were approved U.S. Food Drug Administration treating patients Accordingly, present study reviewed pathogenesis explored updated applications

Language: Английский

---

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Allergology International, Journal Year: 2021, Volume and Issue: 71(1), P. 40 - 46

Published: Nov. 21, 2021

Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. The knowledge on the pathogenesis of AD driving development new drugs. From research results, it has been revealed that Th2 cell-mediated immunity, barrier dysfunction, and pruritus cause a vicious cycle AD. On other hand, Janus kinase (JAK)/signal transducers activators transcription (STAT) pathway are one essential signaling pathways in various inflammatory diseases including In particular, TSLP, IL-4, IL-13 IL-22 occupy an important position for immune reaction. Moreover, experimentally pan-JAK inhibitor suppress STAT3 activation improved function. Furthermore IL-31 contribute lot to chronic AD, transmitted via JAK-STAT pathway. Therefore, JAK inhibitors promising candidates treatment Here we review clinical trials topical dergocitinib; inhibitor, ruxolitinib; JAK1 JAK2 tofacitinib; JAK1, JAK2, JAK3 oral baricitinib; abrocitinib upadacitinib; inhibitor. Significant improvements symptoms were obtained each drug with low frequency adverse events. have ability improve quickly. emergence these would be regarded as innovation atopic dermatitis.

Language: Английский

---

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment

Cellular and Molecular Immunology, Journal Year: 2023, Volume and Issue: 20(5), P. 448 - 474

Published: March 16, 2023

Atopic dermatitis (AD) is the most common inflammatory skin disease, and it considered a complex heterogeneous condition. Different phenotypes of AD, defined according to patient age at onset, race, ethnic background; disease duration; other characteristics, have been recently described, underlying need for personalized treatment approach. Recent advancements in understanding AD pathogenesis resulted real translational revolution led exponential expansion therapeutic pipeline. The study biomarkers clinical studies emerging treatments helping clarify role each cytokine immune pathway will allow addressing unique fingerprints subset. Personalized medicine be ultimate goal this targeted research. In review, we discuss changes concepts both approach highlight scientific rationale behind report recent efficacy data.

Language: Английский

---

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

The Lancet, Journal Year: 2022, Volume and Issue: 401(10372), P. 204 - 214

Published: Dec. 9, 2022

Language: Английский

---

Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies

Journal of the American Academy of Dermatology, Journal Year: 2023, Volume and Issue: 90(2), P. e43 - e56

Published: Nov. 7, 2023

Language: Английский

---

Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

Allergy, Journal Year: 2024, Volume and Issue: 79(6), P. 1501 - 1515

Published: Jan. 8, 2024

Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high burden. In Europe, six new systemic therapies for AD have been approved: biologics dupilumab (anti-interleukin-4 receptor (IL-4R) α in 2017), tralokinumab (anti-IL-13 2021), lebrikizumab 2023), oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib 2020 EU) or JAK1 (upadacitinib 2021 abrocitinib 2022). Herein, we give an update on approvals, long-term safety, efficacy. Upadacitinib highest short-term efficacy among approved therapies. responders, catch up regarding incremental clinical benefit within continuous use. Recently, European Medicines Agency has released recommendations use of JAKi patients at risk (cardiovascular thromboembolic diseases, malignancies, (former) smoking, age ≥65 years). Furthermore, overview emerging currently Phase III trials. Among topical therapies, tapinarof (aryl hydrocarbon receptor), ruxolitinib (JAK1/2i), delgocitinib (pan-JAKi), asivatrep (anti-transient potential vanilloid), phosphodiesterase-4-inhibitors (roflumilast, difamilast) are discussed. current data cord-blood-derived mesenchymal stem cells, CM310 (anti IL-4Rα), nemolizumab (anti-IL-31RA), anti-OX40/OX40L-antibodies, neurokinin-receptor-1-antagonists, difelikefalin (κ-opioid-R) reported.

Language: Английский

---

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence

JID Innovations, Journal Year: 2023, Volume and Issue: 3(3), P. 100195 - 100195

Published: Feb. 24, 2023

Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, nemolizumab. The increase options can be a benefit patients with AD. Meanwhile, it could make difficult physicians choose best among those options. Biologics differ efficacy, safety, route administration, whether or not there is concern about immunogenicity evidence on comorbidities. Among three inhibitors, degree inhibition signal transducer activator transcription differs each inhibitor. Therefore, efficacy safety profiles are different. Physicians who treat AD biologics need understand current individual patients. In this review, we discuss how integrating knowledge mechanisms action potential significant adverse events these drugs, age comorbidities patient help achieve optimal clinical moderate-to-severe refractory topical agents.

Language: Английский

---

Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors

American Journal of Clinical Dermatology, Journal Year: 2024, Volume and Issue: 25(2), P. 179 - 193

Published: Jan. 12, 2024

Language: Английский

---